Curasen Therapeutics, Inc.

Curasen Therapeutics, Inc. company information, Employees & Contact Information

It’s time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN. CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. At CuraSen, we are rethinking the therapeutic approach to treatment of neurodegenerative diseases—and advancing a concept based on restoring a key functionality to a pathway lost early in the degenerating brain. This pathway emanates from the locus coeruleus (LC), site of the earliest pathology seen in these diseases – perhaps the ‘hypocenter’ of neurodegeneration. We began clinical testing of our hypothesis in 2019 using established drugs from other therapeutic areas, which has informed our development program and helped advance our first new chemical entity, CST-2032, to the clinic in September 2020. CuraSen has assembled an impressive team, deeply experienced in the neuroscience, pharmacology and clinical development core to its approach, as well as top tier investor backing, including New Leaf Venture Partners, Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Pappas Capital.

Company Details

Employees
20
Founded
-
Address
930 Brittan Ave,
Phone
(650) 475-2842
Email
in****@****Sen.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Carlos, California
Looking for a particular Curasen Therapeutics, Inc. employee's phone or email?

Curasen Therapeutics, Inc. Questions

News

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study - Yahoo Finance

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study Yahoo Finance

CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension - Clinical Trials Arena

CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension Clinical Trials Arena

CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial - Business Wire

CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial Business Wire

CuraSen treats first subject in neurogenic orthostatic hypotension trial - Clinical Trials Arena

CuraSen treats first subject in neurogenic orthostatic hypotension trial Clinical Trials Arena

Genenexer who sold two startups for $1 billion each named CEO of CuraSen Therapeutics - The Business Journals

Genenexer who sold two startups for $1 billion each named CEO of CuraSen Therapeutics The Business Journals

CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer - Business Wire

CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer Business Wire

Phase 2a cognition, dementia treatment trial underway - Healio

Phase 2a cognition, dementia treatment trial underway Healio

Trial Testing CuraSen’s CST-2032 for Neurodegenerative Disease Begins Dosing - Parkinson's News Today

Trial Testing CuraSen’s CST-2032 for Neurodegenerative Disease Begins Dosing Parkinson's News Today

Alzheimer Disease Pipeline Update: Inside Look at Promising Agents - NeurologyLive

Alzheimer Disease Pipeline Update: Inside Look at Promising Agents NeurologyLive

CuraSen to bring new Alzheimer’s drug into trial in 2024 - Clinical Trials Arena

CuraSen to bring new Alzheimer’s drug into trial in 2024 Clinical Trials Arena

Positive phase 2 results reported for novel combination therapy for Parkinson’s disease - Healio

Positive phase 2 results reported for novel combination therapy for Parkinson’s disease Healio

They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more - The Business Journals

They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more The Business Journals

CuraSen reports positive data from Parkinson’s disease oral therapy trial - Clinical Trials Arena

CuraSen reports positive data from Parkinson’s disease oral therapy trial Clinical Trials Arena

Top Curasen Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant